Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC
BackgroundOsimertinib has been approved as a treatment option for epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). However Abstract Background: Osimertinib has been approved as a treatment option for epidermal growth factor receptor (EGFR) mutated non-small cell...
